

# Anthony Howell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5379169/publications.pdf>

Version: 2024-02-01

578  
papers

49,800  
citations

906

116  
h-index

2127

203  
g-index

590  
all docs

590  
docs citations

590  
times ranked

34215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet, The</i> , 2005, 365, 60-62.	13.7	2,078
2	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2010, 11, 1135-1141.	10.7	1,017
3	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008, 9, 45-53.	10.7	929
4	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. <i>Cancer</i> , 2003, 98, 1735-1744.	4.1	836
5	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. <i>Cancer</i> , 2003, 98, 1802-1810.	4.1	754
6	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
7	First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. <i>Lancet, The</i> , 2002, 360, 817-824.	13.7	708
8	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4273-4278.	1.6	666
9	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	1.6	647
10	Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment. <i>Journal of Clinical Oncology</i> , 2002, 20, 3396-3403.	1.6	626
11	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. <i>International Journal of Obesity</i> , 2011, 35, 714-727.	3.4	573
12	Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer Journal (Sudbury, Mass)</i> , 2001, 7, 377-87.	2.0	566
13	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532
14	Ketones and lactate fuel tumor growth and metastasis. <i>Cell Cycle</i> , 2010, 9, 3506-3514.	2.6	526
15	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	6.3	510
16	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 1041-1048.	13.7	504
17	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. <i>Cancer</i> , 2001, 91, 1191-1200.	4.1	494
18	Dissociation between steroid receptor expression and cell proliferation in the human breast. <i>Cancer Research</i> , 1997, 57, 4987-91.	0.9	480

#	ARTICLE	IF	CITATIONS
19	ATAC trial update. <i>Lancet, The</i> , 2005, 365, 1225-1226.	13.7	467
20	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution. <i>Cell Cycle</i> , 2010, 9, 3276-3296.	2.6	400
21	Evidence for a stromal-epithelial lactate shuttle in human tumors. <i>Cell Cycle</i> , 2011, 10, 1772-1783.	2.6	393
22	Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 1605-1613.	1.6	392
23	Autophagy in cancer associated fibroblasts promotes tumor cell survival. <i>Cell Cycle</i> , 2010, 9, 3515-3533.	2.6	377
24	Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 656-661.	2.5	376
25	Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. <i>Journal of Clinical Oncology</i> , 1996, 14, 2000-2011.	1.6	371
26	ICI 182,780 (Faslodex?). <i>Cancer</i> , 2000, 89, 817-825.	4.1	365
27	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. <i>Journal of Clinical Oncology</i> , 2008, 26, 1051-1057.	1.6	363
28	Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2011, 103, 744-752.	6.3	358
29	Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2006, 7, 633-643.	10.7	356
30	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology, The</i> , 2015, 16, 67-75.	10.7	349
31	The effect of intermittent energy and carbohydrate restriction vs. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. <i>British Journal of Nutrition</i> , 2013, 110, 1534-1547.	2.3	336
32	A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. <i>British Journal of Cancer</i> , 1984, 50, 23-30.	6.4	331
33	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
34	The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 9499-9503.	7.1	316
35	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. <i>Cancer</i> , 1998, 83, 1142-1152.	4.1	315
36	A putative human breast stem cell population is enriched for steroid receptor-positive cells. <i>Developmental Biology</i> , 2005, 277, 443-456.	2.0	312

#	ARTICLE	IF	CITATIONS
37	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. <i>Cancer</i> , 2003, 98, 229-238.	4.1	305
38	The effect of age and menstrual cycle upon proliferative activity of the normal human breast. <i>British Journal of Cancer</i> , 1988, 58, 163-170.	6.4	301
39	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995, 345, 29-30.	13.7	301
40	Ketones and lactate increase cancer cell stemness, driving recurrence, metastasis and poor clinical outcome in breast cancer. <i>Cell Cycle</i> , 2011, 10, 1271-1286.	2.6	295
41	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 187-197.	2.5	285
42	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 4261-4271.	1.6	283
43	The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. <i>British Journal of Cancer</i> , 1989, 60, 121-125.	6.4	275
44	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3411-3415.	1.6	271
45	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
46	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. <i>Journal of Medical Genetics</i> , 2003, 40, 807-814.	3.2	261
47	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. <i>Cell Cycle</i> , 2011, 10, 4047-4064.	2.6	256
48	Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and Metastasis via Oxidative Stress, Mitophagy, and Aerobic Glycolysis. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1264-1284.	5.4	254
49	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. <i>Breast Cancer Research</i> , 2014, 16, 442.	5.0	252
50	Metabolic reprogramming of cancer-associated fibroblasts by TGF- $\beta$ 2 drives tumor growth: Connecting TGF- $\beta$ 2 signaling with Warburg-like cancer metabolism and L-lactate production. <i>Cell Cycle</i> , 2012, 11, 3019-3035.	2.6	249
51	Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 423-467.	22.4	249
52	A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer*. <i>European Journal of Cancer</i> , 1996, 32, 404-412.	2.8	248
53	The autophagic tumor stroma model of cancer. <i>Cell Cycle</i> , 2010, 9, 3485-3505.	2.6	248
54	Risk determination and prevention of breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 446.	5.0	248

#	ARTICLE	IF	CITATIONS
55	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect. <i>Cell Cycle</i> , 2011, 10, 2504-2520.	2.6	245
56	Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. <i>British Journal of Cancer</i> , 1991, 64, 353-356.	6.4	244
57	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. <i>Cell Cycle</i> , 2010, 9, 2423-2433.	2.6	238
58	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 121-133.	2.5	235
59	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <i>Journal of Medical Genetics</i> , 2004, 41, 474-480.	3.2	232
60	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 111-116.	2.5	219
61	Quality of Life of Postmenopausal Women in the ATAC (Arimidex, Tamoxifen, Alone or in T Combination) Trial. <i>Cancer Research and Treatment</i> , 2006, 100, 273-284.	2.5	218
62	Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1045-1051.	2.8	218
63	Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. <i>Cancer Research</i> , 1994, 54, 408-14.	0.9	215
64	Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2001, 19, 1885-1892.	1.6	214
65	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008, 34, S3-S18.	7.7	209
66	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. <i>Cell Cycle</i> , 2012, 11, 2285-2302.	2.6	209
67	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2440-2449.	2.6	208
68	HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells. <i>Cell Cycle</i> , 2010, 9, 3534-3551.	2.6	207
69	Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. <i>American Journal of Clinical Nutrition</i> , 1998, 68, 1431S-1436S.	4.7	206
70	Tamoxifen (Nolvadex™): a review. <i>Cancer Treatment Reviews</i> , 2002, 28, 165-180.	7.7	205
71	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. <i>Cancer</i> , 1998, 83, 1142-1152.	4.1	197
72	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , The, 2011, 12, 496-503.	10.7	196

#	ARTICLE	IF	CITATIONS
73	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004, 13, 61-66.	2.3	195
74	Two-Week Dietary Soy Supplementation Has an Estrogenic Effect on Normal Premenopausal Breast. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4017-4024.	3.6	194
75	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. <i>BMC Cancer</i> , 2008, 8, 155.	2.6	191
76	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. <i>Breast Cancer Research</i> , 2015, 17, 147.	5.0	186
77	Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. <i>British Journal of Cancer</i> , 1996, 74, 300-308.	6.4	182
78	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, fueling tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , 2012, 11, 3599-3610.	2.6	182
79	Understanding the "lethal" drivers of tumor-stroma co-evolution. <i>Cancer Biology and Therapy</i> , 2010, 10, 537-542.	3.4	180
80	Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. <i>British Journal of Cancer</i> , 1991, 64, 349-352.	6.4	176
81	The impact of genetic counselling on risk perception in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1994, 70, 934-938.	6.4	168
82	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007, 14, 169-187.	3.1	165
83	The autophagic tumor stroma model of cancer or "battery-operated tumor growth". <i>Cell Cycle</i> , 2010, 9, 4297-4306.	2.6	165
84	Perception of risk in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1993, 67, 612-614.	6.4	162
85	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. <i>Endocrinology</i> , 1995, 136, 164-171.	2.8	162
86	Mitochondrial metabolism in cancer metastasis. <i>Cell Cycle</i> , 2012, 11, 1445-1454.	2.6	162
87	STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER. <i>Lancet</i> , The, 1984, 323, 588-591.	13.7	160
88	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. <i>Research Policy</i> , 2016, 45, 1996-2007.	6.4	159
89	Estrogen responsiveness and control of normal human breast proliferation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998, 3, 23-35.	2.7	157
90	Origins of breast cancer subtypes and therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 516-525.	4.3	155

#	ARTICLE	IF	CITATIONS
91	A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1986, 4, 1326-1330.	1.6	154
92	Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 1141-1145.	2.8	154
93	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239.	4.1	154
94	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 924-938.	3.4	154
95	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. <i>Breast Cancer Research</i> , 2011, 13, 213.	5.0	153
96	Ketone body utilization drives tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3964-3971.	2.6	152
97	Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. <i>Annals of Oncology</i> , 1992, 3, 611-617.	1.2	151
98	CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 216-227.	4.7	150
99	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 866-873.	13.7	149
100	Mitochondria fuel breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , 2012, 11, 4390-4401.	2.6	147
101	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 1085-1097.	3.4	145
102	Energy transfer in "parasitic" cancer metabolism. <i>Cell Cycle</i> , 2011, 10, 4208-4216.	2.6	144
103	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 135-142.	2.5	144
104	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007, 9, 213.	5.0	142
105	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. <i>European Journal of Cancer</i> , 2006, 42, 1143-1150.	2.8	139
106	Cytokine production and inflammation drive autophagy in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 1784-1793.	2.6	137
107	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". <i>Aging</i> , 2010, 2, 185-199.	3.1	136
108	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets improving meta-analysis and prediction of prognosis. <i>BMC Medical Genomics</i> , 2008, 1, 42.	1.5	134

#	ARTICLE	IF	CITATIONS
109	MRI breast screening in high-risk women: cancer detection and survival analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 663-672.	2.5	133
110	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2318-2324.	2.5	132
111	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. <i>Cell Cycle</i> , 2010, 9, 2412-2422.	2.6	130
112	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet, The</i> , 2020, 395, 117-122.	13.7	128
113	Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex", and Tamoxifen Alone or in Combination" (ATAC) trial. <i>British Journal of Cancer</i> , 2001, 85, 317-324.	6.4	126
114	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 47-66.	4.7	124
115	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment. <i>Cancer Biology and Therapy</i> , 2011, 11, 383-394.	3.4	122
116	Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. <i>Psycho-Oncology</i> , 2000, 9, 462-472.	2.3	121
117	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. <i>Journal of Pathology</i> , 1992, 167, 25-32.	4.5	120
118	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
119	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. <i>International Journal of Cancer</i> , 1991, 48, 206-210.	5.1	117
120	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. <i>Cell Cycle</i> , 2012, 11, 2272-2284.	2.6	116
121	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006, 13, 273-278.	3.1	115
122	Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1329-1336.	6.3	114
123	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. <i>Cancer</i> , 1994, 74, 3135-3141.	4.1	113
124	Energy Balance in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 201-210.	2.5	113
125	Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth. <i>Oncotarget</i> , 2012, 3, 798-810.	1.8	112
126	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth. <i>Cell Cycle</i> , 2011, 10, 4065-4073.	2.6	110



#	ARTICLE	IF	CITATIONS
127	Picking 'winners' in China: Do subsidies matter for indigenous innovation and firm productivity?. <i>China Economic Review</i> , 2017, 44, 154-165.	4.4	110
128	Regulation of human breast epithelial stem cells. <i>Cell Proliferation</i> , 2003, 36, 45-58.	5.3	109
129	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. <i>JAMA Oncology</i> , 2018, 4, 476.	7.1	109
130	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncology</i> , The, 2008, 9, 953-961.	10.7	108
131	Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. <i>Cell Cycle</i> , 2012, 11, 2545-2559.	2.6	107
132	Non-standard management of breast cancer increases with age in the UK: a population based cohort of women >=65 years. <i>British Journal of Cancer</i> , 2007, 96, 1197-1203.	6.4	106
133	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. <i>Cell Cycle</i> , 2012, 11, 4174-4180.	2.6	105
134	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. , 1997, 72, 608-613.		104
135	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. , 1998, 7, 402-412.		104
136	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. <i>Cancer Prevention Research</i> , 2012, 5, 943-951.	1.5	104
137	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 773-779.	10.7	103
138	Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , 2012, 11, 3956-3963.	2.6	103
139	The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. <i>International Journal of Cancer</i> , 1984, 33, 299-304.	5.1	102
140	Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. <i>British Journal of Cancer</i> , 1993, 67, 606-611.	6.4	100
141	Pure oestrogen antagonists for the treatment of advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 689-706.	3.1	100
142	Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects – A Narrative Review of Human and Animal Evidence. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017, 7, 4.	2.1	100
143	Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. <i>Journal of Medical Genetics</i> , 2001, 38, 139-139.	3.2	100
144	Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. <i>International Journal of Cancer</i> , 2002, 101, 555-559.	5.1	99

#	ARTICLE	IF	CITATIONS
145	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. <i>Cancer Biology and Therapy</i> , 2011, 12, 1101-1113.	3.4	99
146	A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1995, 31, 137-142.	2.8	97
147	Understanding the metabolic basis of drug resistance. <i>Cell Cycle</i> , 2011, 10, 2521-2528.	2.6	97
148	The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1567-1572.	0.7	95
149	Carcinomatous meningitis in solid tumours. <i>Annals of Oncology</i> , 1996, 7, 773-786.	1.2	93
150	Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. <i>British Journal of Cancer</i> , 1997, 75, 251-257.	6.4	89
151	Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. <i>BMJ: British Medical Journal</i> , 1988, 297, 772-773.	2.3	88
152	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. <i>Breast Cancer Research</i> , 2008, 10, R26.	5.0	88
153	Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. <i>Clinical Cancer Research</i> , 2001, 7, 2620-35.	7.0	87
154	The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. <i>European Journal of Cancer</i> , 1999, 35, 47-53.	2.8	86
155	Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. <i>International Journal of Cancer</i> , 2007, 121, 1017-1020.	5.1	86
156	MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER. <i>Lancet, The</i> , 1986, 328, 411-414.	13.7	85
157	Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. <i>Lancet, The</i> , 1993, 341, 369.	13.7	84
158	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. <i>Eurasian Geography and Economics</i> , 2011, 52, 119-139.	2.6	84
159	Changes in the extracellular matrix of the normal human breast during the menstrual cycle. <i>Cell and Tissue Research</i> , 1992, 268, 167-177.	2.9	83
160	Screening by mammography, women with a family history of breast cancer. <i>European Journal of Cancer</i> , 1998, 34, 937-940.	2.8	82
161	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <i>Journal of Medical Genetics</i> , 2009, 46, 811-817.	3.2	80
162	Risk reducing mastectomy: outcomes in 10 European centres. <i>Journal of Medical Genetics</i> , 2009, 46, 254-258.	3.2	80

#	ARTICLE	IF	CITATIONS
163	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 279-287.	2.5	80
164	New endocrine therapies for breast cancer. <i>European Journal of Cancer</i> , 1996, 32, 576-588.	2.8	79
165	Serum 1,25-Dihydroxyvitamin D May Be Related Inversely to Disease Activity in Breast Cancer Patients with Bone Metastases <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 118-122.	3.6	77
166	Metabolic reprogramming and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 3280-3289.	2.6	77
167	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 318-328.	7.7	77
168	Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. <i>British Journal of Cancer</i> , 2014, 110, 1681-1687.	6.4	77
169	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. <i>Breast Cancer Research</i> , 2015, 17, 143.	5.0	77
170	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Annals of Oncology</i> , 2011, 22, 857-862.	1.2	76
171	Mitochondrial dysfunction in breast cancer cells prevents tumor growth. <i>Cell Cycle</i> , 2013, 12, 172-182.	2.6	76
172	Late Toxicity Is Not Increased in <i>BRCA1/BRCA2</i> Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7025-7032.	7.0	75
173	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012, 14, R57.	5.0	75
174	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment. <i>Cell Cycle</i> , 2013, 12, 2580-2597.	2.6	75
175	Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e66-e73.	3.8	75
176	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. <i>Technological Forecasting and Social Change</i> , 2022, 174, 121212.	11.6	75
177	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-210.	1.0	75
178	Oestrogen and breast cancer: results from the WHI trial. <i>Lancet Oncology</i> , The, 2012, 13, 437-438.	10.7	74
179	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014, 16, 451.	5.0	74
180	Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. <i>British Journal of Cancer</i> , 1994, 70, 204-211.	6.4	73

#	ARTICLE	IF	CITATIONS
181	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 316-323.	7.1	73
182	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016, 114, 1045-1052.	6.4	73
183	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>World Development</i> , 2017, 94, 200-211.	4.9	73
184	C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. <i>British Journal of Cancer</i> , 1990, 61, 39-45.	6.4	72
185	Faslodex (ICI 182780). <i>European Journal of Cancer</i> , 2000, 36, 87-88.	2.8	72
186	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment. <i>Cell Cycle</i> , 2012, 11, 4402-4413.	2.6	71
187	Fortnightly Review: Familial breast cancer. <i>BMJ: British Medical Journal</i> , 1994, 308, 183-187.	2.3	71
188	CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER. <i>Lancet, The</i> , 1983, 321, 839-843.	13.7	70
189	DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. <i>British Journal of Cancer</i> , 1987, 55, 553-559.	6.4	70
190	Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. <i>Endocrine-Related Cancer</i> , 2006, 13, 617-628.	3.1	69
191	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. <i>Journal of Medical Genetics</i> , 2011, 48, 520-522.	3.2	69
192	Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2021-2034.	2.6	69
193	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. <i>Arimidex Study Group. Cancer</i> , 1998, 83, 1142-52.	4.1	68
194	HISTOLOGICAL DETECTION OF ÅSTROGEN RECEPTOR IN HUMAN BREAST CARCINOMAS. <i>Lancet, The</i> , 1980, 315, 171-173.	13.7	66
195	CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL FOR BREAST CANCER. <i>Lancet, The</i> , 1984, 324, 307-311.	13.7	65
196	Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. <i>British Journal of Cancer</i> , 2006, 94, 460-464.	6.4	65
197	TREATMENT OF ADVANCED PROSTATIC CANCER WITH LHRH ANALOGUE ICI 118630: CLINICAL RESPONSE AND HORMONAL MECHANISMS. <i>Lancet, The</i> , 1983, 322, 415-419.	13.7	63
198	Occurrence of a fetal fibroblast phenotype in familial breast cancer. <i>International Journal of Cancer</i> , 1986, 37, 831-836.	5.1	63

#	ARTICLE	IF	CITATIONS
199	Accelerated aging in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 2059-2063.	2.6	63
200	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. <i>Differentiation</i> , 1990, 42, 199-207.	1.9	62
201	Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. <i>European Journal of Cancer</i> , 1992, 28, 1023-1028.	2.8	62
202	Older women with operable breast cancer are less likely to have surgery. <i>British Journal of Surgery</i> , 2007, 94, 1209-1215.	0.3	61
203	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	1.6	61
204	Epidermal and transforming growth factor $\beta$ in patients with breast tumours. <i>British Journal of Cancer</i> , 1989, 59, 605-609.	6.4	60
205	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. <i>British Journal of Cancer</i> , 2011, 105, 22-27.	6.4	60
206	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. <i>Endocrinology</i> , 1995, 136, 164-171.	2.8	60
207	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 611-618.	2.5	58
208	Indigenous innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. <i>Research Policy</i> , 2015, 44, 1866-1876.	6.4	58
209	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 743-750.	1.6	58
210	Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. <i>BMJ: British Medical Journal</i> , 1988, 296, 811-814.	2.3	57
211	Objective measurement of therapeutic response in breast cancer using tumour markers. <i>British Journal of Cancer</i> , 1991, 64, 757-763.	6.4	57
212	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. <i>Cell Cycle</i> , 2012, 11, 253-263.	2.6	57
213	Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.. <i>BMJ: British Medical Journal</i> , 1985, 290, 185-187.	2.3	56
214	FIBROBLASTS FROM RELATIVES OF PATIENTS WITH HEREDITARY BREAST CANCER SHOW FETAL-LIKE BEHAVIOUR IN VITRO. <i>Lancet, The</i> , 1987, 329, 1455-1457.	13.7	56
215	Uptake of screening and prevention in women at very high risk of breast cancer. <i>Lancet, The</i> , 2001, 358, 889-890.	13.7	56
216	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2014, 15, 1460-1468.	10.7	56

#	ARTICLE	IF	CITATIONS
217	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. <i>Journal of Medical Genetics</i> , 2017, 54, 111-113.	3.2	56
218	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 141-148.	2.5	56
219	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015, 6, 4585-4601.	1.8	55
220	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , 1997, 33, 2183-2193.	2.8	54
221	Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. <i>British Journal of Cancer</i> , 1994, 70, 169-172.	6.4	53
222	Hereditary ovarian cancer and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 4152-4166.	2.6	53
223	Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. <i>Cancer Research</i> , 1987, 47, 300-4.	0.9	53
224	O6-(4-bromothienyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. <i>British Journal of Cancer</i> , 2005, 93, 1152-1156.	6.4	52
225	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: Connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , 2014, 13, 580-599.	2.6	52
226	Agglomeration, (un)related variety and new firm survival in China: Do local subsidies matter?. <i>Papers in Regional Science</i> , 2018, 97, 485-501.	1.9	52
227	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52
228	Allelic imbalance on chromosome I in human breast cancer. II. Microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 24-31.	2.8	51
229	Fulvestrant (Faslodex™): Current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 265-273.	4.4	51
230	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , 2013, 12, 818-825.	2.6	51
231	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
232	The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. <i>Calcified Tissue International</i> , 1991, 49, 433-435.	3.1	50
233	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004, 6, 269-74.	5.0	49
234	Ethnic entrepreneurship, initial financing, and business performance in China. <i>Small Business Economics</i> , 2019, 52, 697-712.	6.7	49

#	ARTICLE	IF	CITATIONS
235	Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. <i>Obesity Reviews</i> , 2006, 7, 33-47.	6.5	48
236	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	2.5	47
237	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 8.	1.5	47
238	Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. <i>International Journal of Cancer</i> , 1994, 59, 25-32.	5.1	46
239	TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN INFILTRATING LOBULAR CARCINOMA OF THE BREAST. <i>Journal of the National Cancer Institute</i> , 1996, 180, 44-49.		46
240	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. <i>Familial Cancer</i> , 2015, 14, 531-538.	1.9	45
241	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4284-4294.	1.6	45
242	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	6.3	45
243	Assessment of Hormone Dependence of Comedo Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1059-1065.	6.3	44
244	Recent advances in endocrine therapy of breast cancer. <i>BMJ: British Medical Journal</i> , 1997, 315, 863-866.	2.3	44
245	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 311-315.	6.4	43
246	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism. <i>Cell Cycle</i> , 2013, 12, 289-301.	2.6	43
247	Parathyroid hormone-related protein(50â€™69) and response to pamidronate therapy for tumour-induced hypercalcaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1629-1633.	0.7	42
248	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , 1996, 41, 31-41.	2.5	42
249	Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy â€™ a longitudinal study. <i>British Journal of Cancer</i> , 2005, 92, 673-680.	6.4	42
250	Vascular effects of aromatase inhibitors: Data from clinical trials. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 95, 143-149.	2.5	42
251	Screening younger women with a family history of breast cancer â€™ does early detection improve outcome?. <i>European Journal of Cancer</i> , 2006, 42, 1385-1390.	2.8	42
252	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. <i>British Journal of Cancer</i> , 2010, 102, 1091-1098.	6.4	42

#	ARTICLE	IF	CITATIONS
253	Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , 2012, 11, 3403-3414.	2.6	42
254	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. <i>European Journal of Surgical Oncology</i> , 2005, 31, 1112-1118.	1.0	41
255	Biomarkers of Dietary Energy Restriction in Women at Increased Risk of Breast Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 720-731.	1.5	41
256	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. <i>British Journal of Cancer</i> , 2018, 118, 1648-1657.	6.4	41
257	Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC.. <i>Cancer Research</i> , 2009, 69, 74-74.	0.9	41
258	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 $\alpha$ , autophagy and ketone body production. <i>Cell Cycle</i> , 2012, 11, 4167-4173.	2.6	40
259	Reverse Warburg Effect in a Patient With Aggressive B-Cell Lymphoma: Is Lactic Acidosis a Paraneoplastic Syndrome?. <i>Seminars in Oncology</i> , 2013, 40, 403-418.	2.2	40
260	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017, 35, 2666-2673.	1.6	40
261	A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 215-222.	2.5	39
262	Industry relatedness, FDI liberalization and the indigenous innovation process in China. <i>Regional Studies</i> , 2020, 54, 229-243.	4.4	39
263	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
264	The endocrine prevention of breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 615-623.	4.7	38
265	Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose. <i>Clinical Breast Cancer</i> , 2011, 11, 204-210.	2.4	38
266	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. <i>International Journal of Cancer</i> , 2020, 146, 2122-2129.	5.1	38
267	High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. <i>British Journal of Cancer</i> , 1993, 67, 825-829.	6.4	37
268	Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 157-162.	2.5	37
269	The effects of oestrogens and anti-oestrogens on cognition. <i>Breast</i> , 2001, 10, 484-491.	2.2	37
270	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. <i>Cancer Prevention Research</i> , 2014, 7, 993-1001.	1.5	37



#	ARTICLE	IF	CITATIONS
271	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. <i>Breast Cancer Research</i> , 2016, 18, 57.	5.0	37
272	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326.	3.9	37
273	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020, 20, 570.	2.6	37
274	Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. <i>European Journal of Surgical Oncology</i> , 1985, 11, 33-6.	1.0	37
275	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet</i> , The, 2005, 365, 1449-1451.	13.7	36
276	Acute Chemotherapy-Related Toxicity Is Not Increased in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Treated for Breast Cancer in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7033-7038.	7.0	36
277	Polymorphisms of <i>CYP19A1</i> and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1191-1198.	2.5	36
278	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/ <i>HER2</i> -Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	7.0	36
279	Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. <i>British Journal of Cancer</i> , 2000, 82, 354-360.	6.4	35
280	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. <i>European Journal of Surgical Oncology</i> , 2000, 26, 711-713.	1.0	35
281	Breast cancer susceptibility variants alter risks in familial disease. <i>Journal of Medical Genetics</i> , 2010, 47, 126-131.	3.2	35
282	Agglomeration, absorptive capacity and knowledge governance: implications for public-private firm innovation in China. <i>Regional Studies</i> , 2020, 54, 1069-1083.	4.4	35
283	Tumour markers in breast cancer. <i>British Journal of Cancer</i> , 1979, 40, 710-718.	6.4	34
284	Prospective assessment of the role of five tumour markers in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 403-410.	4.2	34
285	Cancer experience in the relatives of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 1994, 70, 102-111.	6.4	34
286	Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. <i>Public Health Genomics</i> , 2003, 6, 214-223.	1.0	34
287	Infiltrating lobular carcinoma of the breast: Response to endocrine therapy and survival. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 979-982.	0.7	33
288	Are aromatase inhibitors superior to antiestrogens?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 93, 237-247.	2.5	33

#	ARTICLE	IF	CITATIONS
289	Energy restriction and the prevention of breast cancer. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 263-275.	1.0	33
290	Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 169-174.	2.5	32
291	Fulvestrant (Faslodex <sup>®</sup> ): current status in the therapy of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 151-160.	2.4	31
292	Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005, 366, 431-433.	13.7	31
293	Prevention of breast cancer in the context of a national breast screening programme. <i>Journal of Internal Medicine</i> , 2012, 271, 321-330.	6.0	31
294	The milk protein $\beta$ -casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3972-3982.	2.6	31
295	Breast cancer: Aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002, 8, 1341-1344.	30.7	30
296	Breast density and breast cancer risk factors in a high-risk population. <i>Breast</i> , 2003, 12, 10-16.	2.2	30
297	Lung cancer after treatment for breast cancer. <i>Lancet Oncology, The</i> , 2010, 11, 1184-1192.	10.7	30
298	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 625-629.	2.5	30
299	Can the breast screening appointment be used to provide risk assessment and prevention advice?. <i>Breast Cancer Research</i> , 2015, 17, 84.	5.0	30
300	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	1.6	30
301	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
302	PREDICTIVE CLASSIFICATION OF HUMAN BREAST CARCINOMAS BASED ON LACTALBUMIN SYNTHESIS. <i>Lancet, The</i> , 1977, 310, 14-16.	13.7	29
303	A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. <i>British Journal of Cancer</i> , 1984, 49, 57-63.	6.4	29
304	West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. <i>British Journal of Cancer</i> , 1989, 60, 911-918.	6.4	29
305	Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. <i>European Journal of Cancer</i> , 1993, 29, 209-217.	2.8	29
306	New approaches to the endocrine prevention and treatment of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 39-44.	2.3	29

#	ARTICLE	IF	CITATIONS
307	Mechanisms of Disease: prediction and prevention of breast cancer—cellular and molecular interactions. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 635-646.	4.3	29
308	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 597-601.	2.5	29
309	Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. <i>British Journal of Cancer</i> , 1990, 61, 123-125.	6.4	28
310	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995, 345, 989-990.	13.7	28
311	Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. <i>British Journal of Cancer</i> , 1999, 80, 1265-1270.	6.4	28
312	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. <i>Breast Cancer Research</i> , 2006, 8, 214.	5.0	28
313	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 281-4.	2.3	27
314	Migration stimulating activity in serum of breast cancer patients. <i>Lancet, The</i> , 1991, 337, 130-133.	13.7	27
315	Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. <i>Breast</i> , 1997, 6, 186-189.	2.2	27
316	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 227-237.	2.5	27
317	Energy Restriction for Breast Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2009, 181, 97-111.	1.8	27
318	Heterogeneous impacts of China's economic and development zone program. <i>Journal of Regional Science</i> , 2019, 59, 797-818.	3.3	27
319	Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders'™ views on a low-risk breast screening pathway. <i>BMC Cancer</i> , 2020, 20, 680.	2.6	27
320	The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. <i>British Journal of Cancer</i> , 1982, 46, 757-764.	6.4	26
321	Creating a tumor-resistant microenvironment: Cell-mediated delivery of TNF± completely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , 2013, 12, 480-490.	2.6	26
322	The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. <i>British Journal of Cancer</i> , 1988, 58, 631-634.	6.4	25
323	A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 341-348.	2.3	25
324	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 1.	1.5	25

#	ARTICLE	IF	CITATIONS
325	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1 $\alpha$ ) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998, 92, 1532-1540.	1.4	25
326	Assessment of four monoclonal antibodies as serum markers in breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1990, 26, 1127-1132.	0.7	24
327	Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1992, 68, 434-439.	1.8	24
328	Oestrogen sulphotransferases in malignant and normal human breast tissue. <i>Endocrine-Related Cancer</i> , 1995, 2, 227-233.	3.1	24
329	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2006, 94, 1021-1028.	6.4	24
330	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. <i>International Journal of Cancer</i> , 2022, 150, 73-79.	5.1	24
331	Variation of receptor status in cancer of the breast. <i>British Journal of Cancer</i> , 1983, 47, 511-515.	6.4	23
332	Clinical development of fulvestrant (â€Faslodexâ€™™). <i>Cancer Treatment Reviews</i> , 2005, 31, S3-S9.	7.7	23
333	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>Growth and Change</i> , 2011, 42, 200-226.	2.6	23
334	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. <i>International Journal of Cancer</i> , 2012, 131, 417-425.	5.1	23
335	Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative forBRCA1andBRCA2. <i>Journal of Medical Genetics</i> , 2013, 50, 368-372.	3.2	23
336	Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. <i>Genetics in Medicine</i> , 2022, 24, 1485-1494.	2.4	23
337	Infiltrating lobular carcinoma of the breast.. <i>BMJ: British Medical Journal</i> , 1985, 291, 1371-1372.	2.3	22
338	Hypothesis: Persistent Expression of Fetal Phenotypic Characteristics by Fibroblasts Is Associated with an Increased Susceptibility to Neoplastic Disease. <i>Pathobiology</i> , 1987, 55, 11-17.	3.8	22
339	Cancer genetics clinics. <i>European Journal of Cancer</i> , 1996, 32, 391-392.	2.8	22
340	The future of fulvestrant (â€Faslodexâ€™™). <i>Cancer Treatment Reviews</i> , 2005, 31, S26-S33.	7.7	22
341	Hormone Replacement Therapy and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2010, 188, 115-124.	1.8	22
342	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. <i>Familial Cancer</i> , 2014, 13, 189-196.	1.9	22

#	ARTICLE	IF	CITATIONS
343	Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: Diversity, variability and relationship to prognostic factors. <i>International Journal of Cancer</i> , 1986, 38, 89-96.	5.1	21
344	Prognostic relevance of serum hyaluronan levels in patients with breast cancer. <i>International Journal of Cancer</i> , 1992, 52, 873-876.	5.1	21
345	P27KIP1 expression indicates that steroid receptor-positive cells are a non-proliferating, differentiated subpopulation of the normal human breast epithelium. <i>European Journal of Cancer</i> , 2000, 36, 28-29.	2.8	21
346	New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 420-428.	7.1	21
347	The emerging breast cancer epidemic: early diagnosis and treatment. <i>Breast Cancer Research</i> , 2010, 12, S10.	5.0	21
348	Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. <i>Annals of Oncology</i> , 2018, 29, 504-509.	1.2	21
349	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. <i>Breast</i> , 2019, 45, 1-6.	2.2	21
350	Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. <i>BMC Cancer</i> , 2019, 19, 1089.	2.6	21
351	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>International Journal of Cancer</i> , 2019, 143, 1089-1097.	6.4	21
352	Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. <i>Cancers</i> , 2020, 12, 378.	3.7	21
353	Testosterone and Gonadotrophin Profiles in Patients on Daily or Monthly LHRH Analogue ICI 118630 (Zoladex) Compared with Orchiectomy. <i>British Journal of Urology</i> , 1986, 58, 539-544.	0.1	20
354	Cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. <i>British Journal of Cancer</i> , 1987, 56, 763-773.	6.4	20
355	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 25, 435-439.	2.3	20
356	Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. <i>Journal of Cell Biochemistry</i> , 1997, 73, 690-696.		20
357	Extended role for needle biopsy in the management of carcinoma of the breast. <i>British Journal of Surgery</i> , 2005, 76, 553-558.	0.3	20
358	The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. <i>British Journal of Cancer</i> , 2019, 121, 443-454.	6.4	20
359	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. <i>Scientific Reports</i> , 2021, 11, 2847.	3.3	20
360	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. <i>Breast Cancer Research</i> , 2003, 6, E7.	5.0	19

#	ARTICLE	IF	CITATIONS
361	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 80.e1-80.e7.	1.3	19
362	RASSF1A polymorphism in familial breast cancer. <i>Familial Cancer</i> , 2010, 9, 263-265.	1.9	19
363	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. <i>Economic Geography</i> , 2017, 93, 346-366.	4.6	19
364	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. <i>Breast Cancer Research</i> , 2020, 22, 101.	5.0	19
365	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	8.2	19
366	Bisphosphonates and bone metastases. <i>British Journal of Cancer</i> , 1988, 58, 556-557.	6.4	18
367	ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 61, 145-149.	2.5	18
368	Changes in the normal human breast throughout the menstrual cycle: relevance to breast carcinogenesis. <i>Endocrine-Related Cancer</i> , 1997, 4, 23-33.	3.1	18
369	Significant differences in UK and US female bone density reference ranges. <i>Osteoporosis International</i> , 2010, 21, 1871-1880.	3.1	18
370	Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. <i>British Journal of Cancer</i> , 2012, 107, 230-233.	6.4	18
371	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. <i>Food Science and Nutrition</i> , 2018, 6, 674-680.	3.4	18
372	Personalized prevention in high risk individuals: Managing hormones and beyond. <i>Breast</i> , 2018, 39, 139-147.	2.2	18
373	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. <i>BMC Public Health</i> , 2018, 18, 178.	2.9	18
374	False-negative MRI breast screening in high-risk women. <i>Clinical Radiology</i> , 2017, 72, 207-216.	1.1	17
375	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. <i>Breast</i> , 2018, 37, 148-153.	2.2	17
376	Breast tumour stroma is a prognostic indicator and target for therapy. <i>Breast Cancer Research</i> , 2009, 11, S16.	5.0	16
377	Uptake of breast cancer prevention and screening trials. <i>Journal of Medical Genetics</i> , 2010, 47, 853-855.	3.2	16
378	A New Hormonal Therapy for Prostatic Cancer: Long-term Clinical and Hormonal Response. <i>British Journal of Urology</i> , 1986, 58, 534-538.	0.1	15

#	ARTICLE	IF	CITATIONS
379	Oestrogens, Beatson and endocrine therapy. <i>Endocrine-Related Cancer</i> , 1997, 4, 371-380.	3.1	15
380	Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. <i>European Journal of Cancer</i> , 2002, 38, 13-14.	2.8	15
381	Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. <i>British Journal of Cancer</i> , 2002, 86, 1797-1802.	6.4	15
382	Overview of the impact of conventional systemic therapies on breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, S9-S16.	3.1	15
383	Better Life Expectancy in Women with <i>BRCA2</i> Compared with <i>BRCA1</i> Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1535-1542.	2.5	15
384	Long-term prospective clinical follow-up after <i>BRCA1/2</i> presymptomatic testing: <i>BRCA2</i> risks higher than in adjusted retrospective studies. <i>Journal of Medical Genetics</i> , 2014, 51, 573-580.	3.2	15
385	A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. <i>European Journal of Cancer</i> , 2015, 51, 2725-2731.	2.8	15
386	Minimum wage impacts on Han-minority Workers' wage distribution and inequality in urban china. <i>Journal of Urban Economics</i> , 2020, 115, 103184.	4.4	15
387	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. <i>BMC Cancer</i> , 2021, 21, 637.	2.6	15
388	Automated Breast Tissue Measurement of Women at Increased Risk of Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2006, , 131-136.	1.3	15
389	Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implications for cancer pathogenesis. <i>Exs</i> , 1991, 59, 127-146.	1.4	15
390	The Primary Use of Endocrine Therapies. <i>Recent Results in Cancer Research</i> , 1998, 152, 227-244.	1.8	15
391	Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 658-658.	1.6	15
392	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
393	Preliminary experience with pure antiestrogens. <i>Clinical Cancer Research</i> , 2001, 7, 4369s-4375s; discussion 4411s-4412s.	7.0	15
394	The synthesis of the glycoprotein hormone $\beta$ subunit by human breast carcinomas. <i>European Journal of Cancer</i> , 1979, 15, 693-702.	0.9	13
395	In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 1988, 58, 715-722.	6.4	13
396	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1994, 5, 217-224.	1.2	13

#	ARTICLE	IF	CITATIONS
397	A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 2002, 86, 718-722.	6.4	13
398	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. <i>Familial Cancer</i> , 2007, 6, 287-294.	1.9	13
399	Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4548-4550.	1.6	13
400	Increased Rate of Phenocopies in All Age Groups in <i>BRCA1</i> Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2269-2276.	2.5	13
401	Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). <i>Familial Cancer</i> , 2014, 13, 13-21.	1.9	13
402	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. <i>Journal of Medical Genetics</i> , 2022, 59, 115-121.	3.2	13
403	Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. <i>Women's Health</i> , 2021, 17, 174550652110097.	1.5	13
404	Fetal-like fibroblasts: Their production of migration-stimulating factor and role in tumor progression. <i>Cancer Treatment and Research</i> , 1994, 71, 277-298.	0.5	13
405	The expression of milk fat globule antigens within human mammary tumours: Relationship to steroid hormone receptors and response to endocrine treatment. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 459-467.	0.7	12
406	TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. <i>International Journal of Radiation Biology</i> , 2007, 83, 409-420.	1.8	12
407	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020, 54, 216-221.	2.2	12
408	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK) <small>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</small>	8.7	12
409	Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. <i>Cancer Research</i> , 1987, 47, 296-9.	0.9	12
410	The Effects of Drugs that Cause Neutropenia upon Colony Formation by Bone Marrow Cells in Semi-Solid Agar. <i>Clinical Science and Molecular Medicine</i> , 1974, 46, 619-628.	0.8	11
411	Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1983, 19, 1-4.	0.7	11
412	Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1996, 7, 1051-1057.	1.2	11
413	Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes. <i>European Journal of Cancer</i> , 1997, 33, 2171-2182.	2.8	11
414	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). <i>Lancet</i> , The, 1998, 352, 1222.	13.7	11



#	ARTICLE	IF	CITATIONS
415	Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. <i>Journal of Medical Economics</i> , 1999, 2, 33-43.	2.1	11
416	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 302-309.	2.4	11
417	Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis. <i>Cell Proliferation</i> , 2007, 40, 721-740.	5.3	11
418	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , 2013, 12, 2935-2936.	2.6	11
419	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. <i>Cambridge Journal of Regions, Economy and Society</i> , 0, , rsw024.	3.0	11
420	Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Journal of Medical Genetics</i> , 2022, 59, 133-140.	3.2	11
421	Tamoxifen as an Agonist for Metastatic Breast Cancer. , 1990, , 49-58.		11
422	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1719-1725.	0.7	10
423	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 215-223.	2.5	10
424	Response and Resistance to the Endocrine Prevention of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 201-211.	1.6	10
425	Future use of selective estrogen receptor modulators and aromatase inhibitors. <i>Clinical Cancer Research</i> , 2001, 7, 4402s-4410s; discussion 4411s-4412s.	7.0	10
426	Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 873-876.	0.7	9
427	Treating bony metastases.. <i>BMJ: British Medical Journal</i> , 1991, 303, 429-430.	2.3	9
428	Management of women with a family history of breast cancer in the North West Region of England: training for implementing a vision of the future. <i>Journal of Medical Genetics</i> , 2002, 39, 531-535.	3.2	9
429	The &#x2018;Arimidex&#x2019;, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 207-215.	0.8	9
430	Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 643-643.	6.3	9
431	Are We Ready for Online Tools in Decision Making for <i>BRCA1/2</i> Mutation Carriers?. <i>Journal of Clinical Oncology</i> , 2012, 30, 471-473.	1.6	9
432	Recruitment to the ‘Breast’ Activity and Healthy Eating After Diagnosis (B-AHEAD) Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2018, 17, 131-137.	2.0	9

#	ARTICLE	IF	CITATIONS
433	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 779-785.	2.5	9
434	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 69-76.	1.0	9
435	Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. <i>Breast</i> , 2021, 60, 45-52.	2.2	9
436	ICI 182,780 (Faslodex <sup>®</sup> , <sup>†</sup> ). <i>Cancer</i> , 2000, 89, 817-825.	4.1	9
437	Serum proteins as tumour markers for breast cancer. <i>British Journal of Cancer</i> , 1981, 43, 542-545.	6.4	8
438	Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival. <i>International Journal of Cancer</i> , 1988, 42, 154-158.	5.1	8
439	Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989, 95, 49-57.	0.2	8
440	Normal Breast Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of Human Pregnancy Levels of Estrogen. <i>Cancer Prevention Research</i> , 2009, 2, 257-264.	1.5	8
441	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017, 94, 133-139.	2.6	8
442	“For me it's about not feeling like I'm on a diet”: a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. <i>Journal of Human Nutrition and Dietetics</i> , 2018, 31, 773-780.	2.5	8
443	Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. <i>Genetics in Medicine</i> , 2021, 23, 1969-1976.	2.4	8
444	Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine. <i>British Journal of Cancer</i> , 1992, 66, 79-83.	6.4	7
445	Tamoxifen withdrawal responses “chance observations or clinical clues to antioestrogen resistance?”. <i>Breast</i> , 1994, 3, 199-201.	2.2	7
446	Clues to the mechanisms of endocrine resistance from clinical studies in advanced breast cancer. <i>Endocrine-Related Cancer</i> , 1995, 2, 131-139.	3.1	7
447	Models of new antioestrogen action in vivo: primary tumours. <i>Breast</i> , 1996, 5, 186-191.	2.2	7
448	A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer. <i>Breast Journal</i> , 2003, 9, 213-222.	1.0	7
449	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005, 7, 181-3.	5.0	7
450	Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 521-523.	2.5	7

#	ARTICLE	IF	CITATIONS
451	Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35â€“39 at Increased Familial Risk of Breast Cancer. <i>EClinicalMedicine</i> , 2019, 7, 39-46.	7.1	7
452	Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 677-687.	2.5	7
453	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
454	The Systemic Treatment of Bone Metastases. , 1991, , 121-147.		7
455	Estrogen Deprivation for Breast Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2007, 174, 151-167.	1.8	7
456	Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2001, 49, 471-5.	0.5	7
457	Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 1157-1167.	6.4	7
458	4 New endocrine approaches to breast cancer. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1990, 4, 67-84.	1.0	6
459	Adjuvant Use of Anastrozole in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1524-1526.	1.6	6
460	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007, 17, 210-219.	1.1	6
461	Breast cancer prevention: SERMs come of age. <i>Lancet, The</i> , 2013, 381, 1795-1797.	13.7	6
462	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
463	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. <i>European Journal of Cancer Prevention</i> , 2019, 28, 500-506.	1.3	6
464	Explaining the urban premium in Chinese cities and the role of place-based policies. <i>Environment and Planning A</i> , 2020, 52, 1332-1356.	3.6	6
465	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. <i>Lecture Notes in Computer Science</i> , 2012, , 228-235.	1.3	6
466	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
467	Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programmeâ€”a randomised feasibility study. <i>Pilot and Feasibility Studies</i> , 2021, 7, 220.	1.2	6
468	Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells. <i>British Journal of Cancer</i> , 1980, 42, 616-619.	6.4	5

#	ARTICLE	IF	CITATIONS
469	New endocrine treatments for breast cancer: biological and clinical aspects. <i>Breast</i> , 1996, 5, 170-174.	2.2	5
470	The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. <i>Cancer Treatment Reviews</i> , 1998, 24, 173-184.	7.7	5
471	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 686-692.	5.1	5
472	An early peak of relapse after surgery for breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 255-7.	5.0	5
473	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: More Trouble With Phenocopies. <i>Journal of Clinical Oncology</i> , 2012, 30, 1142-1143.	1.6	5
474	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	5
475	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 591-596.	2.5	5
476	Should unaffected female <i>BRCA2</i> pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?. <i>Familial Cancer</i> , 2019, 18, 377-379.	1.9	5
477	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. <i>Journal of Regional Science</i> , 2020, 60, 1025-1046.	3.3	5
478	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. <i>Cancers</i> , 2021, 13, 3245.	3.7	5
479	Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior <i>BRCA1/2</i> Probability. <i>Cancers</i> , 2021, 13, 4154.	3.7	5
480	A linkage study in seven breast cancer families. <i>American Journal of Human Genetics</i> , 1993, 52, 786-8.	6.2	5
481	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. <i>Bone Marrow Transplantation</i> , 1994, 13, 839-40.	2.4	5
482	Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study. <i>Breast</i> , 2022, 64, 47-49.	2.2	5
483	The therapeutic potential of novel aromatase inhibitors in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 269-279.	4.1	4
484	Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. <i>Journal of the National Cancer Institute</i> , 2002, 94, 307-307.	6.3	4
485	Selective oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2002, 38, 61-62.	2.8	4
486	Retroperitoneal tumour infiltration detected by bone scanning in patients with infiltrating lobular carcinoma of the breast. <i>British Journal of Surgery</i> , 2005, 72, 626-628.	0.3	4

#	ARTICLE	IF	CITATIONS
487	Breast cancer susceptibility variants alter risk in familial ovarian cancer. <i>Familial Cancer</i> , 2010, 9, 503-506.	1.9	4
488	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. <i>BMC Medicine</i> , 2010, 8, 73.	5.5	4
489	Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , .		4
490	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	4
491	Heritability of mammographic breast density. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 2387-2391.	2.0	4
492	The Possible Role of Abnormal Fibroblasts in the Pathogenesis of Breast Cancer. , 1988, , 142-157.		4
493	Hormonal Resistance in Breast Cancer. <i>Handbook of Experimental Pharmacology</i> , 1999, , 205-221.	1.8	4
494	Cyclical Activity and "Ageing" of the Human Breast: Clues to Assessment of Risk and Strategies for Prevention. , 1994, , 27-46.		4
495	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 255-266.	1.2	4
496	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	10.7	4
497	"Should I Take HRT, Doctor?" Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. <i>The Journal of the British Menopause Society</i> , 1995, 1, 9-17.	1.3	3
498	Tamoxifen versus the newer SERMs: what is the evidence?. <i>Annals of Oncology</i> , 2000, 11, 255-266.	1.2	3
499	Strategies for Managing Breast Cancer Risk After the Menopause. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 289-307.	1.8	3
500	PB.17: Inter-observer agreement in visual analogue scale assessment of percentage breast density. <i>Breast Cancer Research</i> , 2013, 15, , .	5.0	3
501	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: Therapeutic implications. <i>Cell Cycle</i> , 2013, 12, 2534-2534.	2.6	3
502	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , .		3
503	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 58-66.	2.5	3
504	New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm. <i>European Journal of Cancer</i> , 2020, 124, 204-206.	2.8	3

#	ARTICLE	IF	CITATIONS
505	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021, 124, 1373-1378.	6.4	3
506	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
507	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
508	Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. <i>Clinical Cancer Research</i> , 2000, 6, 966-70.	7.0	3
509	Cellular aspects of breast cancer: Workshop report. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 21-28.	0.7	2
510	Entry into the tamoxifen prevention trial depends on women's estimates of the population risk of breast cancer. <i>Breast</i> , 1995, 4, 203-204.	2.2	2
511	Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?. <i>Women's Health</i> , 2005, 1, 309-322.	1.5	2
512	Should lifestyle modifications be promoted to prevent breast cancer?. <i>Breast Cancer Research</i> , 2008, 10, S11.	5.0	2
513	10-year analysis of the ATAC trial: wrong conclusion? â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 217.	10.7	2
514	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
515	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 87-94.	2.5	2
516	Local mammographic density as a predictor of breast cancer. <i>Proceedings of SPIE</i> , 2015, , .	0.8	2
517	No strong evidence for increased risk of breast cancer 8â€™26 years after multiple mammograms in their 30s in females at moderate and high familial risk. <i>British Journal of Radiology</i> , 2016, 89, 20150960.	2.2	2
518	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. <i>Familial Cancer</i> , 2017, 16, 173-179.	1.9	2
519	Clustering effects on firm exporting with productivityâ€™enhancing R&D in China. <i>World Economy</i> , 2019, 42, 3168-3187.	2.5	2
520	Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?. <i>Cancers</i> , 2021, 13, 2710.	3.7	2
521	Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. <i>Journal of Clinical Oncology</i> , 2007, 25, 541-541.	1.6	2
522	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2

#	ARTICLE	IF	CITATIONS
523	Selective estrogen receptor modulators (SERMs). , 2002, , 45-62.		2
524	Growth Factorâ€Assisted Chemotherapyâ€The Manchester Experience. Novartis Foundation Symposium, 1990, 148, 201-220.	1.1	2
525	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. Lecture Notes in Computer Science, 2014, , 282-289.	1.3	2
526	Release of Colony-Stimulating Activity from the Isolated Perfused Rat Liver. Clinical Science and Molecular Medicine, 1976, 50, 539-544.	0.8	1
527	Clinical studies with the specific â€pureâ€™ antioestrogen ICI 182780. Breast, 1996, 5, 192-195.	2.2	1
528	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. Current Opinion in Obstetrics and Gynecology, 2005, 17, 429-434.	2.0	1
529	Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. Breast Cancer Research, 2006, 8, 1.	5.0	1
530	Metabolic approaches to breast cancer treatment and prevention. Breast Cancer Research, 2007, 9, .	5.0	1
531	Defining bad stroma in human breast tumors. Cell Cycle, 2011, 10, 3056-3056.	2.6	1
532	Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor Anastrozole. Clinical Chemistry, 2012, 58, 782-783.	3.2	1
533	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. Breast Cancer Research, 2013, 15, 401.	5.0	1
534	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. SSRN Electronic Journal, 2016, , .	0.4	1
535	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. SSRN Electronic Journal, 0, , .	0.4	1
536	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. SSRN Electronic Journal, 2017, , .	0.4	1
537	Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. Journal of Medical Genetics, 2018, 55, 442-448.	3.2	1
538	Relatedness economies, absorptive capacity, and economic catch-up: firm-level evidence from China. Industrial and Corporate Change, 2019, , .	2.8	1
539	Extended gene panel testing in lobular breast cancer. Familial Cancer, 2022, 21, 129-136.	1.9	1
540	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
541	Ethnicity, Start-Up Finance, and Entrepreneurship in China. SSRN Electronic Journal, 0, , .	0.4	1
542	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. SSRN Electronic Journal, 0, , .	0.4	1
543	Estrogen Receptor in Mammary Gland Physiology. , 2000, , 1-16.		1
544	The Origin of Estrogen Receptor $\hat{\pm}$ -Positive and $\hat{\pm}$ -Negative Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 79-86.	1.6	1
545	Picking Winners in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. SSRN Electronic Journal, 0, , .	0.4	1
546	Mammographic Density Over Time in Women With and Without Breast Cancer. Lecture Notes in Computer Science, 2016, , 291-298.	1.3	1
547	Intermediate dose single agent cyclophosphamide chemotherapy of advanced breast cancer. Clinical Oncology, 1983, 9, 251-6.	0.1	1
548	VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer. Cancer Treatment Reports, 1982, 66, 1999-2000.	0.5	1
549	The Use of Milk-Protein Estimation to Assess the Effect of Hormones on Human Breast in Organ Culture. Clinical Science, 1979, 56, 22P-22P.	4.3	0
550	An Automated Test for Antigen- $\hat{\epsilon}$ Antibody Complexes in Human Sera with a Low-Affinity Igm Antiserum. Clinical Science, 1979, 56, 30P-31P.	4.3	0
551	Effect of Altitude on Water Excretion. Clinical Science, 1980, 59, 11P-11P.	4.3	0
552	Localisation of Malignant Germ-Cell Tumours by External Scanning After Injection of Radiolabelled Anti-Alpha-Fetoprotein. Journal of Urology, 1982, 127, 835-836.	0.4	0
553	Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.. BMJ: British Medical Journal, 1984, 289, 831-831.	2.3	0
554	TUMOUR INFORMATION FROM NEEDLE BIOPSY. Lancet, The, 1986, 328, 1342-1343.	13.7	0
555	Clarification of Anastrozole/Megestrol Acetate Trial Program Design. Journal of Clinical Oncology, 2000, 18, 4109-4109.	1.6	0
556	Spreading the word, but not too thinly. Lancet, The, 2004, 363, 165-166.	13.7	0
557	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. Breast Cancer Research, 2005, 7, 1.	5.0	0
558	The future of breast cancer prevention. Breast Cancer Research, 2005, 7, 1.	5.0	0



#	ARTICLE	IF	CITATIONS
559	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2008, 10, .	5.0	0
560	Adherence to hormone therapy in a chemoprevention randomised trial. <i>Breast Cancer Research</i> , 2008, 10, .	5.0	0
561	Detection and management of women at increased risk of breast cancer. <i>Clinical Practice (London,)</i> Tj ETQq1 1 0.784314 rgBT /Overl 0.1	0.1	0
562	Surgical treatment decisions for older patients: The influence of tumour characteristics, patient health and choice. <i>Journal of Geriatric Oncology</i> , 2012, 3, S19-S20.	1.0	0
563	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. <i>Proceedings of SPIE</i> , 2017, 10134, .	0.8	0
564	Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial" British Journal of Cancer, 2020, 122, 925-926.	6.4	0
565	Control of Proliferation in the Normal and Neoplastic Breast. , 2002, , 73-91.		0
566	Incorporating Weight Control into Management of Patients with Early Breast Cancer in the U.K.. <i>Nutrition and Disease Prevention</i> , 2005, , 535-560.	0.1	0
567	Endocrine Therapy. , 2010, , 329-352.		0
568	Fulvestrant. , 2011, , 1459-1463.		0
569	Systemic Treatment and Survival in Carcinoma of the Breast. , 1986, , 303-312.		0
570	The Contribution of Perturbed Epithelial-Mesenchymal Interactions to Cancer Pathogenesis. , 1992, , 61-72.		0
571	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998, 92, 1532-1540.	1.4	0
572	Fulvestrant. , 2015, , 1795-1799.		0
573	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
574	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. <i>Lecture Notes in Computer Science</i> , 2016, , 540-547.	1.3	0
575	Minimum Wages, Spillovers and the Unconditional Wage Distribution in Urban China: Do Ethnic Minorities Benefit?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
576	Heterogenous Impacts of China's Economic and Development Zone Program. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
577	Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , .		0
578	Clinical studies with anastrozole. , 2008, , 101-125.		0